The Union Ministry of Health in New Delhi, India, announced they’ve received “multiple reports” of liver damage occurring in COVID-19 patients treated with remdesivir. Indian health officials said the number of reports has led them to review use of the drug in their country.
This “wonder” drug has been heavily promoted as a promising treatment for COVID-19. In fact, the U.S. government recently bought 500,000 doses of it — which consists of most of the world’s stock of remdesivir for the next three months.
SOURCES:
ThePrint July 3, 2020
The Conversation July 3, 2020